Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...

In biotech, value is created at discrete moments – when data resolves uncertainty. Until then, risk remains. Every dollar ...

The phase 3 LITESPARK-012 trial is testing triplet therapy with oral HIF-2 alpha inhibitor Welireg (belzutifan) given ...

In a 2025 cross-industry survey, 44% of organisations reported experiencing negative consequences from generative AI use, ...

Jazz Pharma's Ziihera and Eli Lilly's Jaypirca, respectively – have been recommended by reimbursement agency NICE for NHS use ...

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Italian drive to increase diagnosis rates in children with severe genetic disorders is achieving transformative results. The ...

Faruk Uzman is Vice President Europe, Middle East, Africa at Boston Scientific. He joined Boston Scientific in 2018 and ...

Delivering this ambition will require collaboration across the cancer ecosystem. Keep Up With Cancer (KUWC), as the ...

The takeover – which, if completed, will be the third acquisition for UCB this decade – involves an upfront payment of $650 ...

Boston-based Kelonia is engaged in the hot area of in vivo CAR-T therapies, presenting encouraging results with its ...

Boehringer Ingelheim has announced it is expanding its global Computational Innovation footprint with a new centre dedicated ...